Related Experiment Video

Updated: Jul 20, 2026

A Flow Cytometry-Based Cell Surface Protein Binding Assay for Assessing Selectivity and Specificity of an Anticancer Aptamer
10:46

A Flow Cytometry-Based Cell Surface Protein Binding Assay for Assessing Selectivity and Specificity of an Anticancer Aptamer

Published on: September 13, 2022

Aptamers as potential probes for cancer

Kathryn Senior

    The Lancet. Oncology
    |September 19, 2006
    PubMed
    Summary

    No abstract available in PubMed .

    More Related Videos

    Exploring Sequence Space to Identify Binding Sites for Regulatory RNA-Binding Proteins
    11:34

    Exploring Sequence Space to Identify Binding Sites for Regulatory RNA-Binding Proteins

    Published on: August 9, 2019

    Kinetic Screening of Nuclease Activity using Nucleic Acid Probes
    06:52

    Kinetic Screening of Nuclease Activity using Nucleic Acid Probes

    Published on: November 1, 2019

    Related Experiment Videos

    Last Updated: Jul 20, 2026

    A Flow Cytometry-Based Cell Surface Protein Binding Assay for Assessing Selectivity and Specificity of an Anticancer Aptamer
    10:46

    A Flow Cytometry-Based Cell Surface Protein Binding Assay for Assessing Selectivity and Specificity of an Anticancer Aptamer

    Published on: September 13, 2022

    Exploring Sequence Space to Identify Binding Sites for Regulatory RNA-Binding Proteins
    11:34

    Exploring Sequence Space to Identify Binding Sites for Regulatory RNA-Binding Proteins

    Published on: August 9, 2019

    Kinetic Screening of Nuclease Activity using Nucleic Acid Probes
    06:52

    Kinetic Screening of Nuclease Activity using Nucleic Acid Probes

    Published on: November 1, 2019

    Related Concept Videos

    Targeted Cancer Therapies02:57

    Targeted Cancer Therapies

    The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
    There are several types of targeted therapies against specific...

    Articles linked to this work by shared authors, journal, and citation graph.

    Efficacy and safety of dabrafenib plus trametinib in adults with differentiated thyroid cancer: a randomised, double-blind, placebo-controlled, phase 3 trial.

    The Lancet. Oncology·2026

    Switching to camizestrant at ESR1 mutation emergence before disease progression during first-line treatment of hormone receptor-positive advanced breast cancer (SERENA-6): extended analysis of a double-blind, placebo-controlled, randomised, phase 3 trial.

    The Lancet. Oncology·2026

    Single, early intravesical instillation of pirarubicin in the prevention of bladder recurrence after radical nephroureterectomy for upper tract urothelial carcinoma (JCOG1403): a multicentre, open-label, randomised, phase 3 trial.

    The Lancet. Oncology·2026
    See all related articles
    JoVE
    x logofacebook logolinkedin logoyoutube logo
    ABOUT JoVE
    OverviewLeadershipBlogJoVE Help Center
    AUTHORS
    Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
    LIBRARIANS
    TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
    RESEARCH
    JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
    EDUCATION
    JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
    Terms & Conditions of Use
    Privacy Policy
    Policies
    Jove
    Visualize
    Contact Us